Human Defences, Vaccination and Drug Development - Worksheets, Questions and Revision
20 original exam-style questions - 11 pages of questions with a full mark scheme - free printable PDF.
Human Defences, Vaccination and Drug Development revision guideMore GCSE Science practiceMock exams
This topic is chapter 4 of GCSE Biology Topic Workbook 2 and chapter 11 of GCSE Biology 10-Minute Tests.
1.18 Human Defences, Vaccination and Drug Development
Vaccination Coverage and Whooping Cough Cases
Original scenario written for Revision Library, styled on the format of UK public health vaccination-coverage reporting (e.g. UKHSA/NHS data summaries). No copied text or figures.
Whooping cough (pertussis) is a bacterial infection that can be serious in young babies. In one country, a national vaccination programme against whooping cough was introduced. Before the programme began, 84000 cases of whooping cough were recorded per year. Several years after the programme began, this fell to 3150 cases per year.
At a secondary school in the same country, 1500 students attend. School nurse records show that 88% of these students have received the MMR (measles, mumps and rubella) vaccine. Public health guidance states that at least 95% vaccination coverage is generally needed to achieve herd immunity against measles within a school-sized population.
Question 1
- skin - acts as a physical barrier to pathogens (and produces sebum, an antimicrobial oil, on its surface) (oe; either point)B1
- stomach acid - kills most pathogens/bacteria that are swallowed with food or drink (oe)B1
- mucus (produced in the airways/nose) - traps pathogens (and dust/particles) before they can reach the lungs (oe)B1
- Answer: Skin: physical barrier that also produces antimicrobial sebum. Stomach acid: kills swallowed pathogens. Mucus in the airways: traps pathogens before they reach the lungs.
Question 2
- phagocytes are white blood cells that engulf and digest pathogens (phagocytosis) (oe)B1
- lymphocytes are white blood cells that produce antibodies specific to a particular antigen on a pathogen (oe)B1
- lymphocytes can also produce antitoxins, which neutralise toxins produced by some pathogens (oe)B1
- Answer: Phagocytes engulf and digest pathogens; lymphocytes produce antibodies (and antitoxins) specific to a particular pathogen.
Question 3
- (a) painkillers relieve symptoms such as pain (oe)B1
- (a) they do this without killing the pathogen / without treating the underlying cause of the illness (oe)B1
- (a) Answer: Painkillers relieve symptoms such as pain, but do not kill the pathogen causing the illness.
- (b) a cold is caused by a virus, and antibiotics are not effective against/do not kill viruses (oe)B1
- (b) viruses reproduce inside the body's own cells, making them very difficult to target with a drug without also damaging the patient's own cells (oe); allow: prescribing antibiotics unnecessarily also contributes to antibiotic resistanceB1
- (b) Answer: A cold is caused by a virus, and antibiotics only work against bacteria; viruses reproduce inside the body's own cells, making them very difficult to target without harming the patient's own cells.
Question 4
- mucus (produced by goblet cells lining the trachea/bronchi) traps pathogens and other particles breathed in with air (oe)B1
- cilia are hair-like structures on the surface of the cells lining the airways (oe)B1
- cilia beat together in a coordinated, wave-like motion (oe)B1
- this moves the mucus (containing trapped pathogens) up and away from the lungs towards the throat, where it is swallowed or coughed out, so fewer pathogens reach/infect the lungs (oe)B1
- Answer: Mucus traps inhaled pathogens; the coordinated beating of cilia sweeps the mucus up and out of the airways towards the throat, so fewer pathogens reach the lungs.
Question 5
- the phagocyte recognises the pathogen as foreign (e.g. by antigens on its surface) and moves towards it (oe)B1
- the phagocyte engulfs/surrounds the pathogen (oe)B1
- the pathogen becomes enclosed within a vesicle inside the phagocyte (oe)B1
- enzymes are released into the vesicle, which digest/destroy the pathogen (oe)B1
- Answer: The phagocyte recognises and moves towards the pathogen, engulfs it into a vesicle, then releases enzymes that digest and destroy it.
Question 6
- herd immunity is when a large enough proportion of a population is immune to (e.g. vaccinated against) a disease that the disease cannot spread easily through the population (oe)B1
- this means people who are not vaccinated (e.g. babies, or people who cannot be vaccinated for medical reasons) are much less likely to come into contact with an infected person (oe)B1
- so they are indirectly protected from catching the disease, even though they are not immune themselves (oe)B1
- Answer: Herd immunity is when enough of a population is vaccinated/immune that a disease cannot spread easily; this indirectly protects unvaccinated individuals because they are much less likely to encounter an infected person.
Question 7
- the antigens in the vaccine trigger a primary immune response (oe)B1
- lymphocytes produce antibodies specific to that antigen, but this response is relatively slow and produces a low concentration of antibodies (oe)B1
- memory lymphocytes (memory cells) are produced and remain in the blood for a long time after vaccination (oe)B1
- if the person later encounters the same/live pathogen, the memory cells recognise the antigen rapidly (oe)B1
- this triggers a faster secondary immune response, producing antibodies more quickly and in much greater quantity than the primary response (oe)B1
- the pathogen is destroyed before the person shows symptoms of the disease, so they are immune (oe)B1
- Answer: Vaccination triggers a primary response, producing antibodies and memory cells; on later exposure to the real pathogen, memory cells trigger a much faster, larger secondary response that destroys the pathogen before symptoms develop, giving long-term immunity.
Question 8
- (a) antibiotics kill bacteria (or stop bacteria growing/reproducing) by a mechanism that specifically targets structures/processes found in bacterial cells (e.g. the bacterial cell wall) (oe)B1
- (a) viruses do not have this bacterial target and reproduce inside the body's own cells, so antibiotics have no effect on them (oe)B1
- (a) Answer: Antibiotics work by targeting structures/processes found only in bacterial cells (such as the cell wall); viruses lack these targets and reproduce inside human cells, so antibiotics cannot affect them.
- (b) overuse of antibiotics increases the rate at which bacteria develop and spread antibiotic resistance, through natural selection: resistant bacteria survive and reproduce, passing on the resistance gene (oe)B1
- (b) this can lead to infections that are difficult or impossible to treat with existing antibiotics, which is a serious risk to public health (oe); allow reference to the need to develop new antibioticsB1
- (b) Answer: Overprescribing antibiotics speeds up the evolution of antibiotic-resistant bacteria (by natural selection), which can create infections that existing antibiotics can no longer treat - a serious public health risk.
Question 9
- number of doublings = 100 / 20 (= 5)M1
- number of cells = 400 x 25 (= 400 x 32)M1
- 12800 (cells) caoA1
- Answer: 12800 cells
Question 10
- (a) e.g. sterilise the Petri dishes, agar and equipment (for example, using an autoclave) before use - to kill any microorganisms already present, preventing contamination of the culture (oe; accept any one valid technique with a correct purpose)B1
- (a) e.g. flame the neck of the bottle containing the bacterial culture (and the inoculating loop) immediately before and after use - to kill microorganisms in the air that could fall in and contaminate the culture, or that could escape (oe; accept any one different valid technique with a correct purpose)B1
- (a) Answer: Any two of: sterilising equipment/agar before use; flaming the culture bottle neck and inoculating loop; working near a Bunsen flame; taping (not sealing) the lid - each to prevent unwanted microorganisms contaminating or escaping the culture.
- (b) 37 C is the temperature at which many pathogens that could harm humans grow best/fastest (oe)B1
- (b) incubating at a lower temperature (25 C or below) reduces the risk of culturing/growing such pathogens, while still allowing the (harmless) bacterium used in this investigation to grow (oe)B1
- (b) Answer: Incubating below 25 C avoids growing conditions that favour pathogens that could infect humans (which grow best near body temperature, 37 C), keeping the investigation safer while still allowing the test bacterium to grow.
- (c) area = π x r2M1
- (c) area = π x 62 (= π x 36)M1
- (c) 113 mm2 (awrt 113 mm2) caoA1
- (c) Answer: 113 mm2
- (d) antibiotic X produced a larger zone of inhibition (113 mm2, allow ft from the candidate's answer to (c)) than antibiotic Y (78.5 mm2) (oe; must show or state a clear numerical comparison)B1
- (d) a larger zone of inhibition means the bacterium is more strongly inhibited by / more sensitive to that antibiotic, so antibiotic X is more effective against this bacterium than antibiotic Y (oe)B1
- (d) Answer: Antibiotic X (zone area 113 mm2) is more effective than antibiotic Y (zone area 78.5 mm2), because a larger zone of inhibition shows the bacterium is more strongly inhibited by antibiotic X.
- (e) valid improvement, e.g. test each antibiotic against more than one species/strain of bacterium (oe; accept: repeat the investigation several times for each antibiotic and calculate a mean zone area)B1
- (e) reason linked to the chosen improvement, e.g. this shows whether the pattern (X more effective than Y) applies generally, rather than being specific to just one type of bacterium (oe; if repeats chosen: reduces the effect of anomalous results/random error on the mean)B1
- (e) further valid related point, e.g. testing a wider range of antibiotic concentrations on the discs would show whether the difference depends on dose, not just the antibiotic used (oe)B1
- (e) correctly links the suggested improvement to increased confidence in the conclusion (e.g. explicitly states that this would make it more certain that antibiotic X really is more effective, rather than the difference being due to chance or to the specific bacterium tested) (oe)B1
- (e) Answer: Test each antibiotic against more than one species/strain of bacterium (or repeat the investigation and calculate a mean zone area for each antibiotic); this shows whether antibiotic X really is more effective in general, increasing confidence that the difference is real rather than due to chance or to the one bacterium tested.
Question 11
- preclinical testing is carried out on cells and tissues in the laboratory, to test for toxicity and efficacy (oe)B1
- preclinical testing is then carried out on live animals, to test for toxicity, an appropriate dosage, and efficacy in a whole living organism (oe)B1
- if preclinical testing is successful, clinical trials on humans can begin, starting with a small number of healthy volunteers given a very low dose, to test for harmful side effects (oe)B1
- if considered safe, trials continue on patients who have the illness, using a range of doses, to find the optimum dose that is most effective with the fewest side effects (oe)B1
- the drug and trial results are peer reviewed by other scientists, and the drug must pass regulatory approval, before doctors can prescribe it (oe)B1
- Answer: Preclinical testing on cells/tissues, then live animals, checks toxicity, dosage and efficacy; clinical trials on healthy volunteers at a low dose test safety, then patients are tested across a range of doses to find the optimum dose; results are peer reviewed and approved before the drug can be prescribed.
Question 12
- a placebo is a substance that looks/tastes identical to the drug being tested but contains no active ingredient (oe)B1
- comparing patients given the drug with patients given the placebo allows researchers to see whether the drug itself is responsible for any improvement, rather than the placebo effect or patients simply expecting to feel better (oe)B1
- in a double-blind trial, neither the patient nor the doctor/researcher assessing them knows who has received the drug or the placebo until the trial ends (oe)B1
- this reduces bias, because the doctor's or patient's expectations cannot influence how symptoms are reported or assessed (oe)B1
- Answer: A placebo (identical in appearance but with no active ingredient) lets researchers separate the drug's real effect from the placebo effect; carrying out the trial double-blind, so neither patient nor assessor knows who received the drug, prevents expectation or bias from affecting the results.
Question 13
- Level 1 Basic, isolated statement(s) about testing a drug, for example a simple reference to preclinical or clinical testing. Little or no evaluation of why the process is needed. The answer may lack scientific detail or structure.1-2
- Level 2 Clear description of most of the main stages of drug testing (preclinical and clinical), with some correct reference to features such as placebo use or double-blind design. Some attempt to evaluate why stages are necessary, though the reasoning may be incomplete or not fully linked together.3-4
- Level 3 A detailed, logically structured description of the full testing and trialling process, from preclinical testing through to clinical trials, correctly referencing placebo use and double-blind design. A well-reasoned evaluation is given, clearly weighing the need for patient safety and reliable results against the time and cost of bringing a new drug to patients.5-6
- Indicative content:
- Preclinical testing is carried out on cells and tissues in the laboratory, to check for toxicity before any human exposure.
- Preclinical testing is then carried out on live animals, to test for toxicity, an appropriate dosage range, and efficacy in a whole organism.
- Clinical trials begin with a small number of healthy human volunteers, given a very low dose, to check the drug does not cause harmful side effects.
- If safe, trials continue on patients with the condition, using a range of doses, to find the optimum dose that gives the greatest benefit with the fewest side effects.
- A placebo may be given to a control group so that the drug's real effect can be separated from the placebo effect or natural recovery.
- Trials are often double-blind, so neither the patient nor the doctor/researcher knows who has received the drug or placebo, reducing bias in the results.
- Large-scale trials involving many patients help to identify rare side effects and confirm the drug works across different types of patient.
- Volunteers and patients must give informed consent and can withdraw at any time, which protects patient welfare during testing.
- Results are peer reviewed by other scientists, and the drug must pass regulatory approval, before doctors can prescribe it.
- The lengthy, multi-stage process balances patient safety and reliable evidence of effectiveness against the delay and cost of bringing a new painkiller to patients who need it.
Question 14
- (a) pregnancy testing - the antibody used binds specifically to hCG (a hormone found in the urine of pregnant women), producing a visible colour change/line if hCG is present (oe)B1
- (a) cancer treatment/diagnosis - antibodies can be produced that bind specifically to antigens found only on cancer cells; they can carry a toxic drug, radioactive substance, or marker directly to the cancer cell without affecting normal healthy cells (oe)B1
- (a) a further valid use, e.g. in research/laboratory diagnosis, to measure or detect the amount of a specific substance (such as a hormone or a pathogen's antigen) in a blood or other sample (oe); accept any two of these three uses, credited once each, up to 3 marksB1
- (a) Answer: Any two of: pregnancy testing (antibody binds specifically to hCG); cancer diagnosis/treatment (antibody binds only to cancer-cell antigens, allowing targeted drug/radioactive delivery); laboratory diagnosis/research (antibody binds specifically to the substance being measured/detected). In each case, specificity for one antigen means only the target substance/cell is detected or affected.
- (b) identifies a valid limitation, e.g. monoclonal antibodies (originally produced using mouse cells) can trigger an immune/allergic reaction in the patient, because the patient's immune system recognises them as foreign (oe; accept other valid limitations, e.g. high cost/time of production)B1
- (b) expands with a linked evaluative consequence, e.g. this can cause side effects such as fever, can limit the dose that can safely be given, or requires the antibody to be 'humanised', increasing production cost and time (oe)B1
- (b) Answer: Monoclonal antibodies can be recognised as foreign by the patient's immune system (as they are often produced using mouse cells), triggering side effects or an allergic reaction; this can limit the safe dose or require costly, time-consuming 'humanising' of the antibody before use.
Question 15
- (a) the antibody has a binding site with a shape that is complementary to the antigen (oe)B1
- (a) only an antigen with a matching/complementary shape can bind to that antibody (oe)B1
- (a) Answer: An antibody's binding site has a shape complementary to one specific antigen, so it will only bind to (and be triggered by) that matching antigen.
- (b) antibodies bind to antigens on the surface of the pathogen itself (oe)B1
- (b) this can label the pathogen for destruction by phagocytes, or cause pathogens to clump together (agglutinate) (oe)B1
- (b) antitoxins instead bind to and neutralise toxins released by the pathogen, making them harmless, rather than acting on the pathogen itself (oe)B1
- (b) Answer: Antibodies bind to antigens on the pathogen itself (marking it for destruction, or causing it to clump); antitoxins instead bind to and neutralise the toxins the pathogen releases.
Question 16
- decrease = 84000 - 3150 (= 80850)M1
- percentage decrease = (decrease / original) x 100 = (80850 / 84000) x 100M1
- 96.3% (awrt 96.2-96.3%) caoA1
- Answer: 96.3% (accept 96.2% to 96.3%)
Question 17
- (a) unvaccinated = 100% - 88% = 12%; number = 12% of 1500 (= 0.12 x 1500)M1
- (a) 180 (students) caoA1
- (a) Answer: 180 students
- (b) no, herd immunity has not been achieved (ft: must be consistent with the coverage figure used, but the correct answer is 'no')B1
- (b) because the school's vaccination coverage (88%) is below the 95% threshold stated as being needed for herd immunity (oe; must compare both figures)B1
- (b) Answer: No - the school's coverage of 88% is below the 95% threshold needed for herd immunity.
Question 18
- (a) same incubation temperatureB1
- (a) same incubation time or same initial bacterial concentration/volume spread, oeB1
- (a) Answer: Any two of: same incubation temperature; same incubation time; same initial bacterial suspension concentration; same volume spread on plates.
- (b) recognises that 10% less volume means fewer bacteria were spread, so colony counts will be artificially lowerM1
- (b) concludes this makes the 4% result appear more effective than it is, introducing bias when comparing concentrations, oeA1
- (b) Answer: The pipette delivered 10% less volume so fewer bacteria were spread and colony counts for 4% will be artificially lower; this makes the 4% appear more effective and introduces bias when comparing concentrations.
- (c) use a calibrated pipette or repeat measurements and discard anomalous plates or increase number of replicates, oeB1
- (c) Answer: Use a calibrated pipette and increase replicates (more plates per concentration) so anomalous volumes have less effect.
Question 19
- Level 3 Detailed explanation linking multiple trial phases to ensuring safety and efficacy; considers increasing sample size, testing in varied populations, detection of rare side effects and the role of post-approval monitoring. Clear, organised reasoning and relevant examples.5-6
- Level 2 Some explanation covering at least two reasons (for example safety and efficacy or sample size and rare side effects) with limited development and some linking between points.3-4
- Level 1 Simple statements such as 'trials check safety' with minimal or no explanation and little linking.1-2
- Indicative content:
- Phase 1 uses small numbers to check safety and dosage; detects common short-term side effects
- Phase 2 tests efficacy and side effects in patients and refines dose, with more participants
- Phase 3 uses large, diverse populations to detect less common side effects and confirm efficacy across groups
- Larger samples increase the chance of finding rare adverse effects and reveal variation in response between ages, sexes or comorbidities
- Post-approval monitoring (phase 4) detects very rare or long-term side effects and real-world effectiveness
- Multiple phases reduce risk of harm, ensure benefit outweighs risk, and provide data for regulators to make informed decisions
Question 20
- a mouse (or other suitable animal) is exposed to the chosen antigen, which stimulates its lymphocytes to produce the specific antibody needed (oe)B1
- lymphocytes that produce this antibody are collected/extracted from the animal (oe)B1
- these lymphocytes are fused with a tumour (myeloma) cell to form a hybridoma cell (oe)B1
- the hybridoma cell combines the ability to divide/proliferate indefinitely (like a tumour cell) with the ability to produce the specific antibody (like the lymphocyte) (oe)B1
- hybridoma cells are cloned and cultured/grown in large quantities to produce a large amount of identical (monoclonal) antibody (oe)B1
- Answer: A mouse is exposed to the chosen antigen so its lymphocytes make the matching antibody; these lymphocytes are fused with a myeloma (tumour) cell to form a hybridoma cell, which both divides indefinitely and produces the antibody; hybridoma cells are then cloned and cultured to produce large quantities of identical, monoclonal antibody.
Mark your answers
Check answers without an account. Some answers can be checked automatically; use the mark scheme to mark the rest.